IP Library Granted Patent US 11,559,535
Granted Patent B2
US 11,559,535 · App. 17/817,731 · Granted Jan 24, 2023

Concentrated liquid pharmaceutical formulations of furosemide

Inventors: Alfredo Grossi (Stoneham, MA); Britt Kostraba (Sandown, NH); Olatokumbo O. Luca Ogunleye (Tewksbury, MA); Shannon Terry (Somerville, MA); Franciscus Koppenhagen (Salem, NH)
Assignee: scPharmaceuticals Inc.
A61K31/635A61K47/10A61K47/18A61K47/32A61M5/14248
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,559,535
App. No.
17/817,731
Granted
Jan 24, 2023
Kind
B2
Abstract

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Claims (32)

1. A liquid pharmaceutical formulation comprising:

furosemide, or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide is from about 60 mg/mL to about 150 mg/mL;

benzyl alcohol, wherein the amount of benzyl alcohol is from about 0.1% (w/w) to about 10% (w/w); and

a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 25 mM to about 150 mM;

wherein the liquid pharmaceutical formulation has a pH of between about 6.5 to about 8.5.

2. The liquid pharmaceutical formulation of claim 1 , wherein the concentration of furosemide is from about 60 mg/mL to about 120 mg/mL.

3. The liquid pharmaceutical formulation of claim 1 , wherein the concentration of furosemide is from about 70 mg/mL to about 90 mg/mL.

4. The liquid pharmaceutical formulation of claim 1 , wherein the amount of benzyl alcohol is from about 0.5% (w/w) to about 5% (w/w).

5. The liquid pharmaceutical formulation of claim 1 , wherein the amount of benzyl alcohol is from about 1% (w/w) to about 3.5% (w/w).

6. The liquid pharmaceutical formulation of claim 1 , wherein the concentration of tromethamine is from about 50 mM to about 125 mM.

7. The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.5.

8. The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.

9. A liquid pharmaceutical formulation comprising:

furosemide, or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide is from about 70 mg/mL to about 100 mg/mL;

benzyl alcohol, wherein the amount of benzyl alcohol is from about 1% (w/w) to about 3.5% (w/w); and

a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 50 mM to about 125 mM;

wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.5.

10. The liquid pharmaceutical formulation of claim 9 , wherein the concentration of furosemide is about 80 mg/mL to 100 mg/mL.

11. The liquid pharmaceutical formulation of claim 9 , wherein the concentration of furosemide is about 80 mg/mL.

12. The liquid pharmaceutical formulation of claim 9 , wherein the liquid pharmaceutical formulation has a pH of between about 7.5 to about 8.5.

13. The liquid pharmaceutical formulation of claim 10 , wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.

14. A liquid pharmaceutical formulation comprising:

furosemide, or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide is from about 80 mg/mL to about 100 mg/mL;

benzyl alcohol, wherein the amount of benzyl alcohol is from about 1% (w/w) to about 3.5% (w/w); and

a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 50 mM to about 125 mM;

wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.

15. The liquid pharmaceutical formulation of claim 14 , wherein the concentration of furosemide is about 80 mg/mL.

16. The liquid pharmaceutical formulation of claim 14 , wherein the concentration of tromethamine is about 50 mM to 100 mM.

17. The liquid pharmaceutical formulation of claim 15 , wherein the concentration of tromethamine is about 50 mM to 100 mM.

18. The liquid pharmaceutical formulation of claim 14 , wherein the concentration of tromethamine is about 75 mM to 125 mM.

19. The liquid pharmaceutical formulation of claim 14 , further comprising one or more of water, an osmolarity adjuster, and a pH adjuster.

20. The liquid pharmaceutical formulation of claim 15 , further comprising one or more of water, an osmolarity adjuster, and a pH adjuster.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2026
From: SCPHARMACEUTICALS INC.
To: MANNKIND CORPORATION
Reel/Frame 075534/0309 →
PATENT SECURITY AGREEMENT Recorded Nov 11, 2025
From: SCPHARMACEUTICALS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 073569/0001 →
RELEASE OF SECURITY INTEREST Recorded Oct 8, 2025
From: PERCEPTIVE CREDIT HOLDINGS IV, LP
To: SCPHARMACEUTICALS INC.
Reel/Frame 072511/0726 →
SECURITY INTEREST Recorded Aug 13, 2024
From: SCPHARMACEUTICALS INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 068261/0702 →
RELEASE OF SECURITY INTEREST Recorded Aug 9, 2024
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: SCPHARMACEUTICALS INC.
Reel/Frame 068244/0093 →
SECURITY INTEREST Recorded Oct 13, 2022
From: SCPHARMACEUTICALS INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 061419/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: GROSSI, ALFREDO; KOSTRABA, BRITT; OGUNLEYE, OLATOKUMBO O. LUCA; TERRY, SHANNON; KOPPENHAGEN, FRANCISCUS
To: SCPHARMACEUTICALS INC.
Reel/Frame 061317/0727 →
Continuity (4)
Continuation 17675043 · Feb 18, 2022
Continuation 17426765
Provisional Application 62799215 · Jan 31, 2019
Related Publication 20220378805A1 · Dec 1, 2022